PE20142371A1 - Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico - Google Patents

Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Info

Publication number
PE20142371A1
PE20142371A1 PE2014001116A PE2014001116A PE20142371A1 PE 20142371 A1 PE20142371 A1 PE 20142371A1 PE 2014001116 A PE2014001116 A PE 2014001116A PE 2014001116 A PE2014001116 A PE 2014001116A PE 20142371 A1 PE20142371 A1 PE 20142371A1
Authority
PE
Peru
Prior art keywords
phenol
propyl
ethyl
methyl
pharmaceutical combination
Prior art date
Application number
PE2014001116A
Other languages
English (en)
Spanish (es)
Inventor
Petra Bloms-Funke
Klaus Schiene
Thomas Christoph
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20142371A1 publication Critical patent/PE20142371A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PE2014001116A 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico PE20142371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05

Publications (1)

Publication Number Publication Date
PE20142371A1 true PE20142371A1 (es) 2015-02-04

Family

ID=40345058

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2014001115A PE20142357A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001117A PE20142372A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2011000206A PE20110291A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2018003303A PE20190914A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001116A PE20142371A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PE2014001115A PE20142357A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2014001117A PE20142372A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2011000206A PE20110291A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
PE2018003303A PE20190914A1 (es) 2008-09-05 2009-09-04 Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Country Status (28)

Country Link
US (1) US20100063148A1 (OSRAM)
EP (2) EP2735338B1 (OSRAM)
JP (4) JP5731387B2 (OSRAM)
KR (3) KR101641519B1 (OSRAM)
CN (2) CN105520924B (OSRAM)
AR (2) AR073361A1 (OSRAM)
AU (3) AU2009289776A1 (OSRAM)
BR (1) BRPI0920521A2 (OSRAM)
CA (1) CA2735857C (OSRAM)
CL (1) CL2011000317A1 (OSRAM)
CO (1) CO6382142A2 (OSRAM)
CY (2) CY1115751T1 (OSRAM)
DK (2) DK2331210T3 (OSRAM)
EC (1) ECSP11010869A (OSRAM)
ES (2) ES2719900T3 (OSRAM)
HR (2) HRP20140663T1 (OSRAM)
HU (1) HUE043278T2 (OSRAM)
IL (3) IL211135A (OSRAM)
LT (1) LT2735338T (OSRAM)
MX (1) MX2011002339A (OSRAM)
PE (5) PE20142357A1 (OSRAM)
PL (2) PL2735338T3 (OSRAM)
PT (2) PT2331210E (OSRAM)
RU (2) RU2674150C1 (OSRAM)
SI (2) SI2331210T1 (OSRAM)
TR (1) TR201904388T4 (OSRAM)
WO (1) WO2010025931A2 (OSRAM)
ZA (1) ZA201101449B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2037965B1 (en) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
JP6005636B2 (ja) 2010-07-06 2016-10-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
RS54711B1 (sr) * 2011-03-04 2016-08-31 Grünenthal GmbH Parenteralno davanje tapentadola
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
HUE036567T2 (hu) * 2011-07-29 2018-07-30 Gruenenthal Gmbh 3-[(1S,2S)-3-(dimetilamino)-1-etil-2-metilpropil]fenol intratekális vagy epidurális adagolásra
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
CA2890270A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
CA3007286A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE60016602T2 (de) 1999-08-20 2005-11-03 Ortho-Mcneil Pharmaceutical, Inc. Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1480639A1 (en) * 2002-02-22 2004-12-01 Warner-Lambert Company LLC Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
SI2012763T1 (sl) * 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
MX360289B (es) * 2007-11-23 2018-10-29 Gruenenthal Gmbh Composiciones de tapentadol.
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika

Also Published As

Publication number Publication date
AU2016203053B2 (en) 2018-01-25
PT2735338T (pt) 2019-05-24
IL237392A0 (en) 2015-04-30
PT2331210E (pt) 2014-08-25
US20100063148A1 (en) 2010-03-11
CO6382142A2 (es) 2012-02-15
TR201904388T4 (tr) 2019-05-21
PE20110291A1 (es) 2011-06-04
JP2015096530A (ja) 2015-05-21
EP2735338B1 (en) 2019-02-06
KR101851120B1 (ko) 2018-04-23
ES2719900T3 (es) 2019-07-16
CA2735857C (en) 2019-05-28
PL2735338T3 (pl) 2019-07-31
JP2017071636A (ja) 2017-04-13
JP2012501986A (ja) 2012-01-26
CN102159284B (zh) 2015-12-09
CY1115751T1 (el) 2017-01-25
RU2571501C2 (ru) 2015-12-20
AU2016203053A1 (en) 2016-06-02
EP2331210B1 (en) 2014-07-09
AU2018202879B2 (en) 2020-03-12
JP2019131578A (ja) 2019-08-08
BRPI0920521A2 (pt) 2018-01-16
ES2513394T3 (es) 2014-10-27
AU2009289776A1 (en) 2010-03-11
CN102159284A (zh) 2011-08-17
HRP20190500T1 (hr) 2019-08-09
DK2735338T3 (en) 2019-04-23
CN105520924A (zh) 2016-04-27
IL211135A (en) 2017-09-28
WO2010025931A3 (en) 2010-06-17
IL237391A (en) 2017-12-31
CN105520924B (zh) 2019-04-09
AR073361A1 (es) 2010-11-03
HUE043278T2 (hu) 2019-08-28
CL2011000317A1 (es) 2011-06-17
EP2735338A1 (en) 2014-05-28
SI2735338T1 (sl) 2019-04-30
HK1159011A1 (en) 2012-07-27
HRP20140663T1 (hr) 2014-10-10
IL211135A0 (en) 2011-04-28
RU2674150C1 (ru) 2018-12-05
AR117613A2 (es) 2021-08-18
PL2331210T3 (pl) 2014-12-31
KR20170048602A (ko) 2017-05-08
KR101641519B1 (ko) 2016-07-21
RU2011112444A (ru) 2012-10-10
SI2331210T1 (sl) 2014-10-30
HK1198145A1 (en) 2015-03-13
MX2011002339A (es) 2011-04-04
AU2018202879A1 (en) 2018-05-17
PE20142357A1 (es) 2015-02-04
LT2735338T (lt) 2019-04-10
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
ECSP11010869A (es) 2011-04-29
IL237392B (en) 2019-08-29
KR20160086981A (ko) 2016-07-20
CY1121492T1 (el) 2020-05-29
PE20142372A1 (es) 2015-02-04
KR101730924B1 (ko) 2017-04-27
KR20110057144A (ko) 2011-05-31
PE20190914A1 (es) 2019-06-26
JP5731387B2 (ja) 2015-06-10
WO2010025931A2 (en) 2010-03-11
CA2735857A1 (en) 2010-03-11
ZA201101449B (en) 2011-10-26
DK2331210T3 (da) 2014-08-11

Similar Documents

Publication Publication Date Title
PE20142371A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2011000603A1 (es) Uso de compuestos de ditiina-tetracarboximidas que sirven para combatir hongos fitopatogenos; procedimiento para combatir dichos hongos; compuestos de ditiina-tetracarboximidas; uso de compuestos de ditiina-diisoimidas; y compuestos ditiina-diisoimidas.
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
CL2011001027A1 (es) Compuestos derivados de 1-(benzo[d][1,3]dioxol-6-il]-n(1h-indol-5-il)ciclopropano carboxamida; moduladores abc; composicion farmaceutica que los comprende; metodo in vitro de incremento de transportadores abc; kit farmaceutico; y su uso en el tratamiento de fibrosis quisticas, problemas metabolicos, del snc, entre otros.
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
NI201000053A (es) Trans-clomifeno para el síndrome metabólico.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
ECSP088515A (es) Mezclas fungicidas que contienen boscalida y pirimetanilo
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
CR9392A (es) O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
ECSP066891A (es) Mezclas fungicidas
ECSP099585A (es) Mezclas fungicidas a partir de 1-metilpirazol-4-ilcarboxanilidas y azolopirimidinilaminas
ECSP12011586A (es) Mezclas fungicidas
NI200900112A (es) Agentes para combatir parásitos en animales.
CR10029A (es) Combinacion de productos activos fungicidas
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
AR022294A1 (es) Combinaciones de productos activos fungicidas.
EA201400667A1 (ru) Микробицидная композиция

Legal Events

Date Code Title Description
FG Grant, registration